This study reports an analysis of clinical, virological, and immunologic outcomes in a cohort of 77 multidrug-experienced AIDS patients during 24 months of highly active antiretroviral therapy (HAART). Our results have shown a reduced risk of AIDS complications, prolonged survival, and immunologic benefit even in the absence of sustained virus suppression. The degree of immunodepression, the risk factors for HIV-1 infection, the use of 2 drugs instead of 3, and a change in protease inhibitor were independently correlated with virological failure. In the majority of studied patients, an increase in CD4 + T cells was observed after HAART. However, the increase was more pronounced in patients who showed a decrease in virus load than in those who did not. Moreover, we observed an absence of relapses among patients who permanently discontinued prophylaxis for Cytomegalovirus retinitis and atypical mycobacterial infections. Peripheral lipodystrophy developed in the majority of patients, regardless of treatment used and virological outcome.
Analysis of T-cell subsets of patients responding to HAART reveals that an increase in memory cells is evident from the first month of therapy, whereas naive cells increase later [3, 13] . Moreover, patients responding to HAART show an amelioration of some T-cell functions [14] .
However, the extent and durability of the beneficial effects of HAART and the long-term toxicity are unknown in patients with advanced HIV-1 disease and severe immunosuppression. In addition, only preliminary immunologic studies of patients who failed to respond to HAART, as determined by HIV-1 RNA levels, have been reported [15] .
To address these issues, we retrospectively analyzed clinical, immunologic, and virological changes in a cohort of AIDS patients followed at our department and enrolled during 1996 into a controlled study of PI treatment. This study was initially designed as compassionate and salvage therapy for those patients who failed to respond to, or who were intolerant of, nucleoside analogues. у600/mL; platelets, у50.000/mL; serum creatinine, р6 times the upper limit of normal; and hepatic aminotransferases and alkaline phosphatase, р5 times the upper limit of normal. In addition, the patients had to have stable clinical conditions during the past 30 days. Of the 77 patients, 59 were men and 18 women. The median age at entry was 36.7 years (range, 27-53 years). Patients belonged to the following risk groups: iv drug users (45 patients), homosexual or bisexual (17) , and heterosexual (15) . According to Centers for Disease Control and Prevention staging for HIV-1 infection [16] , patients were classified as C3 (46) and B3 (31) . Patients at stage C3 received an AIDS diagnosis after a mean time of 21.7 months (range, 1-72 months). At enrollment, the mean time until CD4 ϩ T-cell counts were !200/mL was 34.7 months (range, 4-84 months). The mean CD4 ϩ T-cell count at entry was 24/mL (range, 0-50/mL). The mean plasma HIV-1 RNA load was 4.8 log 10 (range, 4.0-6.1 log 10 ). All patients were NRTI-experienced and PI-naive. The mean previous use of NRTIs as monotherapy or combination therapy was 43.6 months (range, 1-84 months). No concomitant active opportunistic infections were present at enrollment.
Treatments. The initial HAART regimen consisted of indinavir for 44 patients and ritonavir for 33, plus 2 NRTIs: zidovudine plus lamivudine for 30 patients, zidovudine plus didanosine for 13, zidovudine plus zalcitabine for 7, and lamivudine plus stavudine for 3. NRTIs were equally distributed among indinavir and ritonavir recipients. For 24 patients, indinavir or ritonavir treatment was started accompanied by only 1 NRTI (lamivudine for 12, zidovudine for 6, stavudine for 5, and didanosine for 1) because of severe intolerance and side effects or poor compliance with previous treatments. There were no significant differences between patients receiving indinavir or ritonavir in regard to CD4 ϩ T-cell counts, plasma HIV-1 RNA levels, and clinical conditions at baseline. Data analysis was made without regard for the initial PI assigned.
All patients were encouraged to continue primary and secondary prophylaxis for opportunistic infections. However, patients who showed an increase to 1200/mL in CD4 ϩ T-cell counts from baseline values discontinued primary and secondary prophylaxis for atypical mycobacterial infections and secondary prophylaxis for cytomegalovirus infection after the first year of HAART. Primary and secondary prophylaxis for Pneumocystis carinii pneumonia (mainly with trimethoprim-sulfamethoxazole) was continued among all patients until the CD4 ϩ T-cell number was stably 1250/ mL for at least 6 months.
Assessments. At enrollment, the following information was collected: sex, age, risk factor, Centers for Disease Control and Prevention stage, Karnofsky score, weight, time since HIV-1 testing and AIDS diagnosis, time since CD4 ϩ T-cell count was !200/mL, and prior NRTI use (number of drugs and months of therapy). Patients were monitored monthly to assess Karnofsky score, clinical signs and symptoms, HIV-1-related and AIDS-defining events (new or recurrences), and side effects of the drugs. Blood samples were taken at entry and, for the first year, every 45 days for hematology, biochemistry, and liver function analyses. After the first year of follow-up, controls were performed every 3 months. Blood was also taken at entry and every 3 months for determination of CD4 ϩ T-cell counts and plasma HIV-1 RNA levels. Twenty-one of 77 patients were evaluated for delayed-type hypersensitivity against recall antigens and for more detailed T-cell phenotype determinations in addition to CD4 ϩ T cells. To determine the overall efficacy of treatment, clinical, immunologic, and virological outcomes were recorded, including causes of discontinuation of the initially assigned PI. Plasma HIV-1 RNA determination. Plasma HIV-1 RNA load was measured by reverse transcriptase-PCR (Amplicor HIV-1 Monitor; Roche Diagnostic Systems, Branchburg, NJ). The number of HIV-1 RNA copies was calculated on the basis of the manufacturer's reference standards. The threshold of detection for 30 amplification cycles is 200 HIV-1 RNA copies/mL (2.3 log 10 ), whereas the threshold of detection for an ultrasensitive assay is 20 HIV-1 RNA copies/mL [17] .
Immunologic studies. Immunophenotyping of T cells was done by flow cytometry with freshly collected whole blood samples by use of the following monoclonal antibody combinations: CD3-FITC (fluorescein isothiocyanate), CD4-PerCP (peridinin chlorophyll protein), CD45RA-FITC, CD45RO-PE (phycoerythrin), CD28-PE, and HLA-DR-PE (Becton Dickinson, San Jose, CA); CD3-FITC and CD4-PE (Ortho Diagnostic Systems, Raritan, NJ); CD45RO-FITC (Dako, Glostrup, Denmark); and CD8 tricolor (CALTAG Laboratories, South San Francisco, CA). T lymphocytes were quantified according to standard techniques, by use of a Cytoron Absolute instrument (Ortho). Delayed-type hypersensitivity reactions to intradermal administration of recall antigen were evaluated by Multitest IMC (Pasteur Mérieux, Lyon, France) before therapy was begun and then after 12 and 24 months.
Statistical analysis. Quantitative data are summarized by use of means and standard deviations. The normality and the homoscedasticity of the variable distributions were previously controlled, and the appropriate transformations were adopted in the case of violation of the assumptions. Data were then analyzed by the appropriate parametric or nonparametric methods. In particular, the differences between the groups of patients with respect to baseline values were evaluated by analysis of variance with 1 grouping factor. The immunologic parameters during follow-up were analyzed by analysis of variance with 1 grouping factor and 1 repeatedmeasures factor (0 vs. 6 vs. 12 vs. 24 months of therapy). Multiple comparisons were made by use of the appropriate Student's t test (for independent or for paired groups) with Bonferroni's correction. Categorical data are presented as absolute and percentage frequencies and were analyzed by the Pearson's x 2 test. A multivariate stepwise logistic regression was applied to evaluate the prognostic role of the patients' characteristics at enrollment, treatment assigned (1 vs. 2 NRTIs and indinavir vs. ritonavir), first change of therapy (yes vs. no), and reasons for change in terms of virological response. For the purpose of this analysis, risk for HIV-1 infection was categorized into 2 groups on the basis of route of transmission: iv drug use and sexual transmission. ORs with 95% CIs for the variables selected in the final model were computed.
Results
Clinical evaluation. Seventy-seven HIV-1-positive patients started combination therapy that included 1 PI. The mean time of follow-up was 28.8 months (range, 3-31 months). Six patients were lost during follow-up and were therefore excluded from the subsequent evaluations. At the end of the 24th month of follow-up, patients were stratified into 3 groups on the basis ϩ T-cell counts to у50/mL and a decrease of у1 log in plasma HIV-1 RNA levels from baseline values (virological and immunologic response); group II included 32 patients showing increased CD4 ϩ T-cell counts to у50/mL but no significant changes in plasma HIV-1 RNA levels (lack of virological response but with immunologic response); group III included 10 patients who did not show any changes either in CD4 ϩ T-cell number or HIV-1 RNA load (treatment failure). Six of this latter group died during the study period. Two patients showed a significant decrease in HIV-1 RNA levels without changes in CD4 ϩ T-cell count for the first 6 months of HAART. Subsequently, these patients showed an increase in their numbers of CD4 ϩ T lymphocytes, so they were included in group I.
Sixty-five (91.5%) of 71 patients are at present continuing HAART, although not all of them are in the original PI arm. ϩ T-cell counts ranged from 20/mL to 456/ mL. Ten AIDS-defining events (6 relapses and 4 new) occurred during the first 3 months of therapy, as detailed in table 2. Eleven other episodes were observed during follow-up: 8 in the first year between month 4 and month 12 and 3 in the second year. All patients continued HAART during these episodes. No significant differences were seen between the patients in group I and those in group II.
Five patients with cytomegalovirus retinitis permanently discontinued maintenance therapy with ganciclovir and cidofovir after 12 months of HAART, when their CD4 ϩ T-cell counts were stably 1200/mL, and remained free of relapses during the subsequent follow-up. Primary and secondary prophylaxis for atypical mycobacterial infection was discontinued for 22 patients (18 in group I and 4 in group II) after the first year of therapy, and this number increased to 42 (26 in group I and 16 in group II) in the second year. Prophylaxis for P. carinii pneumonia with trimethoprim-sulfamethoxazole was discontinued for 27 patients during the second year of therapy, and their treatment was changed to aerosolized pentamidine. In 1 patient, Kaposi's sarcoma skin lesions disappeared during HAART without any other specific treatment. Table 3 reports HAART modifications during follow-up. Twenty (60.6%) of 33 patients treated with ritonavir and 16 (36.3%) of 44 treated with indinavir changed the initial PI assigned because of treatment failure, poor compliance, intolerance, or toxicity (renal pain or stones in 5 patients, elevation in aminotransferase levels in 3, and hypertriglyceridemia in 2). Intolerance was mainly related to ritonavir treatment (8 of 11 patients), with which poor compliance was more frequent. Poor compliance and failure, despite change in treatment assigned, was mainly observed in group II (20 of 32 patients).
Clinical evidence of peripheral lipodystrophy was observed in 28 patients (45.9%), 13 in group I and 15 in group II, after 24 months of follow-up. Hyperlipidemia (increase in cholesterol and/or triglyceride levels) was observed in 37 patients (60.6%), 15 in group I and 22 in group II ( ). The occurrence of P = NS 1 or both of these side effects involved 77% of treated patients during follow-up. No correlations were seen between specific PI assignment and the frequency of peripheral lipodystrophy and/or hyperlipidemia. Plasma HIV-1 RNA levels. A significant mean reduction in plasma HIV-1 RNA levels (11.5 log 10 copies/mL) was observed among group I patients at month 6 and maintained during the follow-up ( vs. baseline; figure 1A ). Twenty P ! .001 patients (30.7%) reached undetectable levels of plasma viremia (!200 copies/mL) and 9 (13.8%) experienced a stable virus load reduction of у1 log. However, among 12 patients with persistent undetectable plasma viremia and high CD4 ϩ T-cell counts (1400/mL), the ultrasensitive assay demonstrated only 6 patients with !20 copies/mL. In 32 patients (49.2%), HIV-1 RNA levels persisted unchanged or showed a decrease of !1 log during follow-up, even though in 6 cases a temporary reduction of 11 log in the first months of therapy was observed. However, despite the high HIV-1 RNA levels, patients' peripheral CD4 ϩ T-cell counts consistently increased (figure 1B). Stepwise logistic regression applied to the 61 patients in groups I and II selected risk category for infection, NRTI treatment initially assigned, and first PI change as the factors significantly and independently associated with virological response. In particular, patients with iv drug use as route of infection showed a higher risk of virological nonresponse than did patients who acquired infection by the sexual route (OR, 15.65; 95% CI, 1.60-153.14). Moreover, patients who initially received 1 NRTI with the PI showed a higher risk of virological failure than did patients receiving 2 NRTIs also if previously used (OR, 5.79; 95% CI, 1.21-27.70). Finally, patients who changed PI for any reason showed a higher risk of virological nonresponse than did patients who continued to receive their initial treatment (OR, 41.15; 95% CI, 4.31-392.16).
Immunologic results. ϩ T-cell counts in both groups were analyzed for the 3 years preceding HAART and compared with the values observed during follow-up (figure 2). No significant differences were present in the pre-HAART period.
Analysis of HLA-DR expression on CD8 ϩ T cells, done for a subset of 21 patients, did not show a significant variation over time; however, when this result was analyzed comparing group I versus group II, a difference was observed after 24 months ( cells/mL vs. cells/mL). 78 ‫ע‬ 63 170 ‫ע‬ 150 CD4 ϩ CD45RA ϩ (naive), CD4 ϩ CD45RO ϩ (memory), and CD8 ϩ CD28 ϩ T-cell counts were significantly increased 24 months after HAART was begun ( ), without differences P ! .005 between the 2 groups.
Delayed-type hypersensitivity testing against tuberculin purified protein derivative, streptokinase-streptodornase, and tetanus, diphtheria, Proteus, Candida, and Trichophyton antigens was negative for all patients examined before starting therapy. After 24 months of the HAART regimen, delayed-type hypersensitivity against 1 or a few antigens was present in only 4 patients.
Discussion
In this study, we have observed a reduced risk of AIDS complications, prolonged survival, and immunologic benefit even in the absence of sustained virus suppression among multidrug-experienced AIDS patients treated with HAART.
An estimated 10%-20% of patients receiving HAART fail to respond, and another 10%-30% of patients have only partial virus suppression [18] . However, the majority of clinical trials were of selected patient populations, probably with less severe clinical conditions in comparison with our patients [1, 3] . Longterm virological, immunologic, and clinical effects of HAART in advanced stages of HIV-1 disease are still under investigation, and several factors should be considered, mainly the characteristics of treated patients [3, 5, 10] . Our cohort included HIV-1-infected patients with CD4
ϩ T lymphocyte counts !200/mL for 12 years before starting HAART and a history of extensive (13 years) previous NRTI use in monotherapy or combination therapy. These characteristics may have affected the overall efficacy observed, at least in terms of virological response. In fact, 150% of patients showed little or no decrease in plasma HIV-1 RNA load during the study period. The pattern of incomplete or transient decrease in HIV-1 RNA observed in this study is similar to that shown in other reports [15, [19] [20] [21] .
Starting from the first months of therapy, both groups of patients showed an immunologic response, at least in terms of an increase in CD4 ϩ T lymphocytes, though of a different magnitude (17-fold in group I and 9-fold in group II). Moreover, a successful high rate of responses in terms of clinical signs was seen, both for patients reaching low plasma viremia and for those without a virological response. In our cohort, primary and secondary prophylaxis for P. carinii pneumonia with aerosolized pentamidine was continued because, at the time of the study, there were no available data on this issue. Cytomegalovirus retinitis disappeared among patients with relapses who discontinued secondary prophylaxis, as described elsewhere [22, 23] . This could be attributable to an expansion of specific memory cells able to react against cytomegalovirus, as demonstrated elsewhere [3, 14] . Localized cutaneous Kaposi's sarcoma, as described elsewhere [24] , seemed to better respond to HAART in our patients. These observations strongly support the possibility of stopping primary and secondary prophylaxis for patients who achieve a stable and persistent rise in CD4 ϩ T lymphocyte counts, as recently demonstrated by Furrer et al. [25] .
As expected, patients who continued their initial assigned therapy showed a better response than did those who changed treatment regimen for any reason. Also, beginning with 2 NRTIs in association with the PI was significantly correlated with a better virological response. On the other hand, the initial use of indinavir or ritonavir did not correlate with virological outcome. Sexual transmission was also significantly associated with a better virological response, perhaps because of higher compliance with therapy among all patients than was observed among iv drug users. However, all of these patients had been previously treated with у1 NRTIs, and therefore the possibility that they were partially resistant to these drugs cannot be ruled out. Patients who did not show a decrease in HIV-1 RNA had [9, 15] . To explain this phenomenon, the following hypotheses can be put forward: possible action of PIs on nonviral targets participating in the mechanisms of CD4 ϩ T-cell depletion [20, 26] ; isolation of virus strains resistant to HAART that are less cytopathic than the wild type [27] ; or transient or partial reduction in virus load (!0.5 log 10 ) sufficient to allow cell proliferation or to decrease mortality rate and thus to compensate for the loss of CD4 ϩ cells [21] . Regarding these hypotheses, we performed virus strain phenotyping for a few patients with high CD4 ϩ T-cell counts in group II. The analysis showed the presence of nonsyncytium-inducing strains (data not shown). Further studies will be needed to verify these hypotheses.
In the course of HIV-1 infection, viral replication plays a pivotal role [28, 29] . However, ∼20% of patients rapidly progress to AIDS, even in the presence of low viral replication, and conversely, a smaller proportion of patients (10%-25%) with high virus load do not show rapid progression [29, 30] . Therefore, although viral replication is the main cause of impairment of immune responses, it represents only 1 of the aspects.
Despite the early intolerance shown by some patients, severe adverse events were infrequent and were managed by drug discontinuation and switching to the other PI. Significant elevations in hepatic enzymes and modifications of other metabolic parameters were generally reversible and not associated with clinical symptoms, with the exception of kidney stones or renal pain related to indinavir use. Moreover, in long-term PI administration, occurrence of initially unknown adverse events, such as the recently described lipodystrophy syndrome [12, 13] , must be taken into consideration. Only a few studies have analyzed the incidence of lipodystrophy syndrome and related metabolic alterations [31] , and none have followed a similar cohort of patients for this length of time. In our study, occurrence of these clinical and metabolic manifestations is unrelated to the virological or immunologic response. Higher increases in triglyceride levels, necessitating PI discontinuation, were occasionally reported among ritonavir recipients, but mild to moderate hyperlipidemia progressively occurred in the majority of patients, with or without clinical signs of peripheral fat redistribution. These side effects have not led to HAART discontinuation, because of the absence of other alternative regimens and the lack of information about long-term risks associated with these manifestations. On the other hand, HAART also achieved very impressive clinical and immunologic results also in patients who lacked a virological response; therefore, in our opinion, its discontinuation without the possibility of alternative therapy did not seem ethical. We do not exclude that in the near future a critical reevaluation of this decision could be made.
The definition and management of virological failure still need to be better determined [30, 32] . Changing treatments when a detectable plasma HIV-1 RNA level is confirmed would prevent the further evolution of drug-resistant mutants. However, the low number of subsequent therapeutic options may suggest a more conservative approach [33] . This is particularly true in experienced patients at an advanced stage of HIV-1 disease, such as those in our cohort, who have been heavily pretreated with nucleoside analogues. For these patients, therapeutic strategies are very poor and alternative regimens problematic.
In conclusion, our data demonstrate the efficacy of HAART for NRTI-pretreated patients with advanced HIV-1 disease. Understanding the correlations between clinical outcome and changes in CD4 ϩ T-cell counts and HIV-1 RNA levels requires further investigation. Our results suggest that in many patients, immunologic and clinical recovery may be independent of the virological response, and even a partial reduction in virus load may be beneficial.
